wire - news in brief

« BACK

Administration/Government



Results 1 - 50 of 157.
1 2 3 4 Next »

Medicine/Pharmacology - Administration/Government
23.10.2017
Novartis combination adjuvant therapy Tafinlar + Mekinist receives FDA Breakthrough Therapy Designation for stage III BRAF V600 mutation-positive melanoma patients
Novartis combination adjuvant therapy Tafinlar + Mekinist receives FDA Breakthrough Therapy Designation for stage III BRAF V600 mutation-positive melanoma patients Breakthrough Therapy Designation ba
Medicine/Pharmacology - Administration/Government
10.10.2017
Medicine/Pharmacology - Administration/Government
06.10.2017
FDA approves Roche cobas Zika as first commercially-available donor screening test for Zika virus
FDA approves Roche cobas Zika as first commercially-available donor screening test for Zika virus Zika virus infection is linked to neurological complications in adults, and brain defects in fetuses
Environment/Sustainable Development - Administration/Government
06.10.2017
Instrument of ratification deposited: Paris climate agreement to enter into force for Switzerland on 5 November 2017
Bern, 06.10.2017 - Switzerland deposited its instrument of ratification in New York on 6 October 2017, making it an official party to the Paris Agreement.
Administration/Government
29.09.2017
Medicine/Pharmacology - Administration/Government
22.09.2017
Novartis and The Max Foundation transform pioneering cancer access program for people in lower-income countries
CMLPath to Care(TM) collaboration replaces Glivec International Patient Access Program (GIPAP) with a new, independent, patient-centered access model   GIPAP was introduced 15 years ago and has provi
Administration/Government - Agronomy/Food Science
29.08.2017
Administration/Government - Medicine/Pharmacology
23.08.2017
Switzerland once again a full member of partnership-funded EU innovation programmes
Bern, 23.08.2017 - On 23 August, the Federal Council approved the agreements on Switzerland's participation in the Eurostars-2 and the Active and Assisted Living research and development programmes.
Business/Economics - Administration/Government
15.08.2017
The smart grid analysts
The smart grid analysts
ETH spin-off Adaptricity has developed a piece of software that can be used to analyse the increasingly intelligent power grids.
Administration/Government
11.07.2017
Use-inspired basic research: external report recommends targeted adjustments
Use-inspired basic research: external report recommends targeted adjustments
The Swiss National Science Foundation (SNSF) commissioned an external evaluation of its funding category "use-inspired basic research" last year. Based on the evaluators' recommendations, it has now decided to introduce targeted changes in its processes. Based on a mandate from the federal government, the Swiss National Science Foundation promotes scientific research; the focus is on basic research.
Medicine/Pharmacology - Administration/Government
10.07.2017
Positive phase III results for Roche’s emicizumab in haemophilia A published in The New England Journal of Medicine
Positive phase III results for Roche's emicizumab in haemophilia A published in The New England Journal of Medicine HAVEN 1 showed emicizumab reduced bleed rate by 87% compared with on-demand bypassing agents All 12 secondary endpoints in HAVEN 1 were positive, including an intra-patient comparison that showed emicizumab reduced bleed rate by 79% compared to prior prophylactic bypassing agents Data from HAVEN 1 in adults and adolescents and inte
Administration/Government - Careers/Employment
06.07.2017
Ten years of the European Research Council: positive record from Swiss perspective
Bern, 06.07.2017 - An event was held in Geneva on 6 July to mark the tenth anniversary of the European Research Council (ERC).
Medicine/Pharmacology - Administration/Government
27.06.2017
Fewer pills, more flexibility in dosing: Roche’s new Esbriet tablet formulation approved in Europe for mild to moderate idiopathic pulmonary fibrosis (IPF)
Fewer pills, more flexibility in dosing: Roche's new Esbriet tablet formulation approved in Europe for mild to moderate idiopathic pulmonary fibrosis (IPF) New immediate-release tablet formulation of
Administration/Government
08.06.2017
Mobilizing Swiss Research in Asia
Mobilizing Swiss Research in Asia
ETH Zurich to serve as the Leading House for Swiss Science and Technology programme in the Asia-Pacific region.
Medicine/Pharmacology - Administration/Government
05.06.2017
Rocheâ? s Perjeta-based regimen reduced the risk of invasive cancer returning compared to Herceptin and chemotherapy in HER2-positive early breast cancer
APHINITY study shows Rocheâ??s Perjeta-based regimen reduced the risk of invasive cancer returning compared to Herceptin and chemotherapy in HER2-positive early breast cancer Phase III study confirms
Media - Administration/Government
02.06.2017
Medicine/Pharmacology - Administration/Government
24.05.2017
New data at ATS add to the body of evidence for Roche’s Esbriet (pirfenidone) in idiopathic pulmonary fibrosis (IPF)
New data at ATS add to the body of evidence for Roche's Esbriet (pirfenidone) in idiopathic pulmonary fibrosis (IPF) In new post hoc analyses of phase III data, Esbriet reduced the risk of death in p
Administration/Government - Careers/Employment
17.05.2017
Stable demand for SNSF funding
Stable demand for SNSF funding
In 2016, the Swiss National Science Foundation (SNSF) supported around 3200 research projects involving more than 14,000 researchers from universities, universities of applied sciences, universities
Medicine/Pharmacology - Administration/Government
10.05.2017
Roche provides update on phase III study of TECENTRIQ (atezolizumab) in people with previously treated advanced bladder cancer
Roche provides update on phase III study of TECENTRIQ (atezolizumab) in people with previously treated advanced bladder cancer IMvigor211 study did not meet its primary endpoint of overall survival (
Medicine/Pharmacology - Administration/Government
20.04.2017
NIH study in NEJM shows Novartis drug eltrombopag as first-line therapy with standard treatment improves responses in severe aplastic anemia
NIH study in NEJM shows Novartis drug eltrombopag as first-line therapy with standard treatment improves responses in severe aplastic anemia NIH study found 58% of patients with treatment-naïve severe aplastic anemia (SAA) achieved a complete response when eltrombopag was given at the initiation of and concurrently with standard immunosuppressive therapy   The historical complete response rate was 10% for untreated patients with SAA on immunosup
Medicine/Pharmacology - Administration/Government
17.04.2017
Roche announces positive interim results for emicizumab in phase III study of children with haemophilia A
Roche announces positive interim results for emicizumab in phase III study of children with haemophilia A Emicizumab prophylaxis reduced the number of bleeds in children with haemophilia A and inhibi
Administration/Government
05.04.2017
Federal Council approves public law agreement on innovation park and provides initial funding guarantees
Bern, 05.04.2017 - On 5 April 2017 the Federal Council entered into agreements with the Switzerland Innovation Foundation and approved guarantees for an initial CHF 150 million of funding for the Swiss Innovation Park.
Medicine/Pharmacology - Administration/Government
21.03.2017
Novartis’ Cosentyx is first and only IL-17A inhibitor to potentially modify the course of psoriasis
New data suggests that disease modification with Cosentyx may be achievable for around 20% of patients following one year of treatment   Patients with longer disease duration before treatment with Co
Medicine/Pharmacology - Administration/Government
18.03.2017
New analysis shows Novartis Entresto improves glycemic control in reduced ejection fraction heart failure patients with diabetes
New post-hoc analysis of PARADIGM-HF data demonstrates Entresto lowered levels of HbA1c (a measure of glycemic control) by 0.26% vs.
Event - Administration/Government
16.03.2017
Medicine/Pharmacology - Administration/Government
02.03.2017
Roche’s Perjeta regimen helped people with an aggressive type of early breast cancer live longer without their disease returning compared to Herceptin and chemotherapy
Phase III APHINITY study shows Roche's Perjeta regimen helped people with an aggressive type of early breast cancer live longer without their disease returning compared to Herceptin and chemotherapy
Medicine/Pharmacology - Administration/Government
01.03.2017
Better health services for the chronically ill
Better health services for the chronically ill
The SNSF is launching the National Research Programme ‘Smarter Health Care'. 29 research teams will be looking for ways of providing better and more cost-efficient health services for people with chronic diseases.
Administration/Government - Careers/Employment
08.02.2017
Assessing assessments
Assessing assessments
How someone learns depends largely on how they are assessed. To help ETH retain its leading position in the education of young talent, about 100 educational decision makers from ETH Zurich attended a two-day retreat on the topic of assessment.
Administration/Government
01.02.2017
Internationalisation - Essential to success
Internationalisation - Essential to success
ETH Zurich is the most international university in the world. This recognition from the Times Higher Education World University Rankings emphasises the value and importance of international exchange for academia, the economy, and society.
Business/Economics - Administration/Government
31.01.2017
Opening doors in Asia
Opening doors in Asia
Both science and Swiss businesses are benefiting from the ETH science hub in Singapore. The newly founded Switzerland Technology Impact Platform (STIP) is helping Swiss SMEs to gain a foothold in Asia.
Life Sciences - Administration/Government
20.12.2016
Administration/Government
15.12.2016
Administration/Government - Careers/Employment
14.12.2016
A record for EPFL's startups: close to CHF 400 million raised in 2016
A record for EPFL's startups: close to CHF 400 million raised in 2016
Start-ups linked to EPFL raised almost CHF 400 million this year - that's over 50% more than in 2014, the last record year.
Medicine/Pharmacology - Administration/Government
12.12.2016
Novartis launches SMS for Life 2.0 in Nigeria to help improve access to essential medicines
SMS for Life 2.0 launches for the first time in Kaduna State, Nigeria's third most populous region, in collaboration with the Kaduna State Ministry of Health   Program uses smartphones and tab
Administration/Government - Event
07.12.2016
Event - Administration/Government
05.12.2016
SwissFEL inauguration
SwissFEL inauguration
Today, on 5 December 2016, the Paul Scherrer Institute PSI held an inauguration ceremony for its new large-scale research facility Swiss FEL, with Johann N. Schneider-Ammann, President of the Swiss Confederation, in attendance.
Medicine/Pharmacology - Administration/Government
14.11.2016
Novartis presents new Cosentyx data showing long-lasting efficacy in psoriatic arthritis over 3 years including patient-reported pain
Cosentyx data show sustained improvements in the signs and symptoms of psoriatic arthritis (PsA) in approximately 80% of patients over 3 years *   New data show that with Cosentyx the high ACR response rates are consistently maintained in PsA, with no reduction from Year 1 to Year 3   New head-to-head clinical trials planned in ankylosing spondylitis (AS) and PsA to compare Cosentyx versus Humira **/*** The digital press release with multimedia
Administration/Government
25.10.2016
Scientific cooperation between Switzerland and Australia
Bern, 25.10.2016 - The second meeting of the Swiss-Australian joint committee for cooperation in the areas of science, research and cooperation was held today in Bern.
Medicine/Pharmacology - Administration/Government
08.10.2016
Novartis’ Tafinlar (dabrafenib) + Mekinist (trametinib) demonstrate superior overall survival benefit in advanced melanoma patients at three-year follow up
Novartis' Tafinlar (dabrafenib) + Mekinist (trametinib) demonstrate superior overall survival benefit in advanced melanoma patients at three-year follow up Latest data confirm an estimated 45% of pat
1 2 3 4 Next »

 
 
Jobs listed on